The main therapeutic areas for which Servier’s research is renowned are cancer, cardiovascular disease, endocrinology, neuroscience, rheumatology, and venous disease.
30 innovative medicines have been developed from in-house research since the company’s beginnings in 1954, the last three of which are each first of their therapeutic class.
Servier is currently collaborating with approximately 30 public and private research organizations throughout the world, including many biotech companies who chose to work with Servier among a large number of candidate companies.
68% of Servier’s medicines are produced in France. As 90% of Servier medicines are consumed outside France.
The Division of Biotechnology & Biomarker Research is dedicated to the application of technologies and expertise from genomics, proteomics, bioinformatics, cellular imaging and histopathology to the validation of target hypothesis and the discovery, characterization and application of biomarkers in discovery and early clinical development.
Our objective within this consortium is to interact with leading research scientists and clinicians from academic and industrial partners to empower improved standardization, comparison and validation of different methodologies / technologies in liquid biopsy research (CTCs , ctDNA in particular) and apply these methods in controlled clinical trials to demonstrate the potential clinical utility of evaluating different markers via blood sampling. Servier will participate by supporting a post-doctorate position and in-kind contributions during the 5y duration of the program in WPs 0, 1, 2. In addition, a minor contribution via biostatistics in bioinformatics expertise will be proposed in WP3.